Since 2019, our institution has implemented a neoadjuvant chemoimmunotherapy protocol for locally advanced HNSCC patients, employing a regimen comprising paclitaxel, gemcitabine, platinum-based agents, fluorouracil, and programmed cell death protein 1 (PD-1) inhibitors. Here, PDCD1 is linked to head and neck squamous cell carcinoma.